DDInter4 DDInter740
Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Abarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Flecainide
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Abarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Abarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aripiprazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Abarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} (Compound) downregulates {v} (Gene) EXT1
EXT1 {u} (Gene) is downregulated by {v} (Compound) Flecainide
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Abarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tizanidine
Tizanidine {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Flecainide (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) downregulates EXT1 (Gene) and EXT1 (Gene) is downregulated by Flecainide (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Flecainide (Compound)